Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Human Blastoid-Based Platform for Post-Implantation IVF Optimization and Therapeutic Screening

Objectif

Since the first successful IVF birth in 1978, the technology has become a cornerstone of assisted
reproduction, driven by the trend toward delayed parenthood. While IVF now accounts for roughly
5% of births in Europe, its overall efficiency remains low, with only about 25% of cycles resulting in a
live birth. A major bottleneck is the high rate of failure during implantation. Due to the limited
availability of human embryos and ethical restrictions, IVF optimization has historically relied on
mouse models. However, while pre-implantation development is similar between mice and humans,
their post-implantation trajectories diverge significantly, limiting their translational relevance. This
highlights the urgent need for a reliable, ethical, and predictive model of early human development
after implantation. Under the ERC-CoG program, we developed human blastoids, blastocyst-like
structures that accurately mimic key features of pre-implantation human embryogenesis. The present ERC-PoC project will translate
this platform into a pre-commercial application by screening compounds to improve IVF outcomes.
Our expected deliverables include: (i) a validated blastoid-based screening platform, (ii) patented natural compounds with therapeutic potential for IVF, and (iii) a
business and IP framework for investors, partners, and funding bodies.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2025-POC

Voir tous les projets financés au titre de cet appel

Institution d’accueil

INSTITUT FUER MOLEKULARE BIOTECHNOLOGIE GMBH
Contribution nette de l'UE
€ 150 000,00
Adresse
DR BOHRGASSE 3
1030 Wien
Autriche
Région
Ostösterreich Wien Wien
Type d’activité
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Liens
Coût total
Aucune donnée

Bénéficiaires (1)